Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom CEO Schuh Resigns; CFO Zaniboni Named Acting-CEO

Click here to read an updated version of this article.

NEW YORK, Feb. 9 (GenomeWeb News) - Toni Schuh has resigned as CEO of Sequenom, the company said last night in a terse statement.

 

Steve Zaniboni, Sequenom's chief financial officer, will take over Schuh's position while the company looks for a permanent replacement, Sequenom said. Schuh has also resigned as a Sequenom director, and the company said it has not yet tapped a replacement.

 

Schuh will remain as a consultant to Sequenom for up to 12 months, the company said.

 

According to  Pharmacogenomics Reporter, a GenomeWeb News publication, Schuh has been under pressure from his board to revive the high-throughout genotyping company after a fling with drug discovery hurt revenue growth and investor confidence, and  nearly cost the company its position on the Nasdaq exchange.

 

Since abandoning its drug-discovery business in August, Sequenom has turned its attention toward selling its flagship MassArray genotyping platform -- which has lagged behind rival instruments -- and has signed on new customers. The San Diego-based company is also attempting to grow its presence in the molecular diagnostics industry, and its share price has also rebounded.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.